Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04493502 | A Study of LY3041658 in Adults With Hidradenitis Suppurativa | PHASE2 | COMPLETED | 72 | — | — | Aug 26, 2020 | Oct 13, 2022 | Apr 28, 2023 | 20 | United States, Australia |
The HiSCR is defined as at least a 50% reduction in the total abscess and inflammatory nodule count (sum of abscesses and inflammatory nodules \[AN count\]) with no increase in abscess count (A count) and no increase in draining fistulae count (DF count) relative to baseline. Non-responder imputation (NRI): Participants with missing data were considered non-responders.
| Arm | Type | Description |
|---|---|---|
| LY3041658 | EXPERIMENTAL | Participants received 600 mg LY3041658 administered intravenously (IV) once every 2 weeks (Q2W). |
| Placebo | PLACEBO_COMPARATOR | Placebo administered IV. Participants will switch to 600 mg LY3041658 administered IV after week 16. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Administered IV |
| LY3041658 | DRUG | Administered IV |
Inclusion Criteria: * Have a diagnosis of HS for at least 6 months * Have HS lesions in at least 2 different anatomic areas * Have inadequate response or intolerance to a 28 day course of oral antibiotics * Have a total count of abscesses and inflammatory nodules greater than or equal to 4 * Agree ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Lutikizumab, Upadacitinib |
| Incyte Corporation | INCY | 6 | PHASE3 | Povorcitinib, povorcitinib, Ruxolitinib, Vehicle |
| Novartis AG Sponsored ADR | NVS | 12 | PHASE3 | secukinumab, Remibrutinib Dose A, Remibrutinib Dose B, CFZ533, LYS006 |
| MoonLake Immunotherapeutics Class A | MLTX | 4 | PHASE3 | Sonelokimab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | Brivekimig, SAR445399 |
| Insmed Incorporated | INSM | 1 | PHASE2 | Brensocatib |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Eltrekibart |
| Pfizer Inc. | PFE | 1 | PHASE2 | Ritlecitinib |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Zasocitinib |
| Zura Bio Limited Class A | ZURA | 1 | PHASE2 | Tibulizumab Dose A, Tibulizumab Dose B |
| Sonoma Pharmaceuticals, Inc. | SNOA | 2 | PHASE1 | SBT777101 |
| Evommune, Inc. | EVMN | 1 | EARLY_PHASE1 | EVO101 |